MONTREAL, May 6 /CNW Telbec/ - Aegera Therapeutics is pleased to announce
the initiation of a Phase 2a, proof-of-concept, clinical trial for AEG33773, a
novel, orally bio-available small molecule therapeutic addressing the
under-served market of painful diabetic neuropathy.
The Phase 2a study, entitled A Multicenter, Randomized, Double-Blind,
Placebo-Controlled Study Comparing the Safety and Efficacy of AEG33773 versus
Placebo in Patients with Painful Diabetic Peripheral Neuropathy will evaluate
the efficacy, safety and tolerability of three dose levels of AEG33773 in
diabetic patients suffering from significant neuropathic pain. This study is
underway in Canada and Aegera will soon initiate trial sites in the Unites
States, where the IND has recently cleared the FDA regulatory review process,
and also in Europe, where the regulatory documents are now under review by the
appropriate regulatory authorities.
"We are very excited about this first Phase 2 study for AEG33773 which
has demonstrated robust preclinical in vivo data in multiple models of
neuropathic and inflammatory pain. Furthermore, AEG33773 could have the
potential to treat chronic pain conditions well beyond painful diabetic
neuropathy." commented Dr. Jacques Jolivet, M.D., Senior Vice President
Clinical Development of Aegera.
"With the successful conclusion of the Phase 1 safety studies for
AEG33773 and the initiation of the first Phase 2a trial in diabetic patients
suffering from significant neuropathic pain, we are now focused on
successfully completing this trial while identifying an appropriate
development partner; this will ensure that our novel agent is developed
rapidly and effectively for its first indication while exploring additional
indications so as to expand this franchise on a global basis." added Dr.
Michael J. Berendt, Aegera's President and CEO.
About Aegera Therapeutics Inc. (www.aegera.com)
Aegera Therapeutics is a clinical stage biotechnology company focused on
developing targeted therapeutics for major unmet medical needs. Aegera has
three programs in clinical development. In addition to AEG33773, Aegera is
- AEG35156 targets the key anti-apoptotic protein XIAP, and is in
multiple randomized Phase II clinical trials;
- HGS1029(AEG40826) is a small molecule pan-IAP inhibitor in Phase 1
development. It has demonstrated very promising preclinical activity
and is partnered with Human Genome Sciences, Inc. (Nasdaq: HGSI) for o
ncology in all countries except Japan.
For further information:
For further information: Donald Olds, MSc, MBA, Chief Operating Officer
& CFO, (514) 288-5532 *295, firstname.lastname@example.org